$BLNC
Balance Labs, Inc.

2024 Q1 Form 10-Q Financial Statement

#000149315224018584 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q1
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $65.72K $4.370K $36.28K
YoY Change 81.15% -93.27% -64.27%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $65.72K $4.370K $36.28K
YoY Change 81.16% -93.27% -64.27%
Operating Profit -$65.72K -$36.28K
YoY Change 81.16% 6.56%
Interest Expense $56.91K -$124.4K $56.32K
YoY Change 1.05% -24.94% -129.97%
% of Operating Profit
Other Income/Expense, Net -$51.23K -$51.00K
YoY Change 0.44% -72.86%
Pretax Income -$116.9K -$128.8K -$87.28K
YoY Change 33.98% -34.41% -60.68%
Income Tax
% Of Pretax Income
Net Earnings -$116.9K -$128.8K -$87.28K
YoY Change 33.99% -34.41% -60.68%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 21.67M shares 21.67M shares 21.67M shares
Diluted Shares Outstanding 21.67M shares 21.67M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $189.4K $220.7K $375.2K
YoY Change -49.53% -42.54% 75.4%
Cash & Equivalents $75.76K $112.8K $221.1K
Short-Term Investments $113.6K $107.9K $154.1K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $0.00
Total Short-Term Assets $189.4K $220.7K $375.2K
YoY Change -49.53% -48.56% -15.13%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $189.4K $220.7K $375.2K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $189.4K $220.7K $375.2K
YoY Change -49.53% -48.56% -58.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.871M $2.785M $2.162M
YoY Change 32.76% 30.65% 145.24%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.699M $1.699M $1.699M
YoY Change 0.0% 0.0% 0.0%
Long-Term Debt Due $280.0K $280.0K $280.0K
YoY Change 0.0% 0.0% 0.61%
Total Short-Term Liabilities $4.849M $4.764M $4.141M
YoY Change 17.11% 15.89% 2.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $483.0K
YoY Change -100.0% -100.0% 2.4%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $483.0K
YoY Change -100.0% -100.0% 2.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.849M $4.764M $4.141M
Total Long-Term Liabilities $0.00 $0.00 $483.0K
Total Liabilities $4.849M $4.764M $4.624M
YoY Change 4.87% 3.77% 2.55%
SHAREHOLDERS EQUITY
Retained Earnings -$5.472M -$5.355M -$5.061M
YoY Change 8.13% 7.67%
Common Stock $2.167K $2.167K $2.167K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.660M -$4.543M -$4.249M
YoY Change
Total Liabilities & Shareholders Equity $189.4K $220.7K $375.2K
YoY Change -49.53% -48.56% -58.03%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q1
OPERATING ACTIVITIES
Net Income -$116.9K -$128.8K -$87.28K
YoY Change 33.99% -34.41% -60.68%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$37.05K -$32.81K -$14.25K
YoY Change 160.04% -24.51% 4.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$37.05K -32.81K -$14.25K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$37.05K -32.81K -$14.25K
YoY Change 160.04% -4.71%
FREE CASH FLOW
Cash From Operating Activities -$37.05K -$32.81K -$14.25K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2024Q1 us-gaap Depreciation
Depreciation
usd
CY2023Q1 us-gaap Depreciation
Depreciation
usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4040 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3806 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
16000 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
18782 usd
CY2024Q1 us-gaap Salaries And Wages
SalariesAndWages
45678 usd
CY2023Q1 us-gaap Salaries And Wages
SalariesAndWages
13689 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
65718 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
36277 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-65718 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36277 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
5687 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
5315 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
56912 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
56318 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-51225 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-51003 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-116943 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-87280 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4542883 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4659826 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4161312 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4161312 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-87280 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4248592 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4248592 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-116943 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2834 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2835 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
5687 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
5315 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-45000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
82751 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
30514 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37045 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14246 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37045 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14246 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112809 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
235311 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75764 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
221065 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37045 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75764 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75764 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5472041 usd
CY2024Q1 BLNC Working Capital Deficit
WorkingCapitalDeficit
-4659826 usd
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zRssv05bxSqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zI4mr4FxKcn4">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
66432 shares
CY2024Q1 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
113599 usd
CY2024Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.71
CY2024Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
5687 usd
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 share for 8 share reverse stock split
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zFs8guBdhw2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zQgj6wo3oj35">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of March 31, 2024, and December 31, 2023, the carrying value of marketable securities was $<span id="xdx_906_eus-gaap--MarketableSecurities_iI_c20240331_z2Rwek8G0Z1e" title="Marketable securities">113,599</span> and $<span id="xdx_905_eus-gaap--MarketableSecurities_iI_c20231231_zSMCZPUt3WSl" title="Marketable securities">107,912</span>, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
113599 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
107912 usd
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2024Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1379 usd
CY2023Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1197 usd
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11316 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11316 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11316 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11316 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
5670 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
8504 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
494330 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
491496 usd
CY2024Q1 BLNC Notes Receivable Unamortized Allowance Current Percentage
NotesReceivableUnamortizedAllowanceCurrentPercentage
1 pure
CY2024Q1 BLNC Notes Receivable Unamortized Allowance Current
NotesReceivableUnamortizedAllowanceCurrent
141000 usd
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
5670 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
8504 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
494330 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
491496 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
106850 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
106850 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
173192 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
173192 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2835 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11340 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
494330 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
491496 usd

Files In Submission

Name View Source Status
0001493152-24-018584-index-headers.html Edgar Link pending
0001493152-24-018584-index.html Edgar Link pending
0001493152-24-018584.txt Edgar Link pending
0001493152-24-018584-xbrl.zip Edgar Link pending
blnc-20240331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
blnc-20240331_lab.xml Edgar Link unprocessable
blnc-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blnc-20240331_cal.xml Edgar Link unprocessable
blnc-20240331_def.xml Edgar Link unprocessable